A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) — Stella

Recruiting

Back to Allergic Asthma trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

United States

Children's Mercy Hospital, Kansas City, Missouri

Key details

Phase

Large-scale testing

Sponsor

Bridgette Jones

Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Enrollment target

~300 participants

Started

April 2021

Primary completion

September 2026

Age range

6 Years – 17 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov